Follow
Therapy
Therapy: is the attempted remediation of a health problem, usually following a diagnosis. In the medical field, it is usually synonymous with treatment.
OCT 22, 2019 | 9:00 AM
DATE: October 22, 2019 TIME: 9:00am PDT, 12:00PM EDT...
OCT 22, 2019 | 8:00 AM
Calprotectin is a member of the S100 family of calcium binding proteins, being a hetero dimmer of S100A8/9 and accounts for 60% of the protein in the cytoplasm of neutrophils. It is released...
OCT 10, 2019 | 1:30 PM
Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In thi...
OCT 10, 2019 | 12:00 PM
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
OCT 10, 2019 | 10:30 AM
Accumulation of structural variations (SVs) across the genome is a known trigger factor for oncogenesis. Structural mutations have been clearly implicated in a number of cancers, most notably...
OCT 10, 2019 | 10:30 AM
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic ap...
OCT 10, 2019 | 9:00 AM
Copy-number alterations and chromosomal translocations are widespread in cancer and frequently causing oncogenic mutations that drive tumorigenesis and therapy resistance. Despite their preva...
OCT 10, 2019 | 9:00 AM
Blockade of CTLA-4 and PD-1, members of the B7/CD28 family, have proven to be the most successful cancer immunotherapies to date. While the current therapeutic focus remains on B7/CD28 family...
OCT 09, 2019 | 12:00 PM
This presentation will review the utility of multiparametric MRI (mpMRI) and genomic testing in the management of early stage prostate cancer and show when and if such tests should be used al...
